References
- Adachi Y, Suzuki H, Sugiyama Y. (2001). Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharmaceut Res 18:1660–1668.
- Benet LZ, Cummins CL, Wu CY. (2003). Transporter–enzyme interactions: implications for predicting drug–drug interactions from in vitro data. Curr Drug Metab 4:393–398.
- Benet LZ, Cummins CL, Wu CY. (2004). Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharmaceut 277:3–9.
- Choi DH, Chang KS, Hong SP, Choi JS, Han HK. (2008a). Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in Rats. Biopharmaceut Drug Disposit 29:45–50.
- Choi DH, Shin WG, Choi JS. (2008b). Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol 64:445–449.
- Eichelbaum M, Remberg EG, Schomerus M, Dengler HJ. (1979). The metabolism of DL-[14C]verapamil in man. Drug Metab Disposit 7:145–148.
- Fleckenstein A. (1977). Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17:149–166.
- Holtzman CW, Wiggins BS, Spinler SA. (2006). Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26:1601–1607.
- Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. (1993). Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332–337.
- Lea AP, McTavish D. (1997). Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemia. Drug 53:828–847.
- Lennernas H. (2003). Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141–1160.
- Lewis GR, Morley KD, Lewis BM, Bones PJ. (1978). The treatment of hypertension with verapamil. NZ Med J 87:351–354.
- McDonnel CG, Shorten G, Van Pelt FN. (2005). Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesis 60:747–753.
- Parks JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. (2008). Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 38:1240–1251.
- Pauli-Magnus C, Von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF. (2000). Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 293:376–382.
- Saitoh H, Aungst BJ. (1995). Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharmaceut Res 12:1304–1310.
- Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum. (1976). Physiological disposition of verapamil in man. Cardiovasc Res 10:605–612.
- Wu X, Whitheld LR, Stewart BH. (2000). Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-monocarboxylic acid co-transporter. Pharmaceut Res 17:209–215.